Processa Pharmaceuticals filings document formal 8-K and amended 8-K disclosures for a clinical-stage biopharmaceutical issuer. The records cover material events involving licensing and term-sheet matters, Nasdaq listing compliance, executive-officer status changes and compensatory arrangements, and shareholder-vote reporting.
The company's filings also describe capital-structure and charter actions, including amendments to its certificate of incorporation, authorized-share changes, reverse stock split mechanics, common-stock rights and related governance approvals. These disclosures frame Processa's public-company status, equity structure and corporate governance alongside its development-stage pharmaceutical business.
Processa Pharmaceuticals director Geraldine Pannu reported an open-market purchase of Common Stock. On March 31, 2026, she bought 2,072 shares at $2.535 per share, bringing her direct holdings to 2,188 shares. This was a straightforward open-market buy with no derivatives involved.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng bought additional company stock. On March 31, 2026, he made an open-market purchase of 2,136 shares of Processa common stock at $2.535 per share.
Following this transaction, Ng directly holds 3,649 common shares. He also has indirect ownership of 3,488 shares through an account labeled "George Ng IRRA FOB George Ng" and 800 shares through the "Ng Cha Family Trust," giving him a larger combined economic stake in PCSA.
Processa Pharmaceuticals, Inc. Chief Business & Strategy Officer Patrick Lin made an open-market purchase of 1,603 shares of common stock at $2.535 per share. Following this transaction, he directly holds 3,356 shares. In addition, 1,740 shares are held indirectly through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy bought shares in the company. On the open market, she purchased 1,854 shares of common stock at $2.535 per share, increasing her direct holdings to 3,110 shares. She also has indirect ownership of 333 shares held by CorLyst, LLC.
Processa Pharmaceuticals’ Chief Development Officer, Bigora Sian, purchased common stock in the open market. On March 31, 2026, Sian bought 2,107 shares of Processa Pharmaceuticals common stock at $2.535 per share, increasing direct ownership to 3,711 shares. The filing also reports indirect ownership of 267 shares held through CorLyst, LLC.
Processa Pharmaceuticals director Baluch Khoso bought shares of the company in the open market. On this transaction date, he purchased 2,269 shares of Common Stock at an average price of $2.535 per share in an open-market purchase. Following this trade, he directly owns 2,325 Processa Pharmaceuticals common shares.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on Next Generation Cancer (NGC) therapies that modify how existing chemotherapy drugs are metabolized or distributed to improve safety and efficacy. Its lead candidate, NGC-Cap (PCS6422 plus capecitabine), has completed a Phase 1B trial in refractory gastrointestinal cancers and is now in a global Phase 2 trial in advanced or metastatic breast cancer, temporarily paused after dosing 20 patients pending an interim analysis expected in the first half of 2026.
The company is also advancing NGC-Iri (PCS11T), a next-generation irinotecan, and is seeking to monetize two non-oncology assets, PCS12852 for gastroparesis and PCS499 for kidney disease. Processa emphasizes a proprietary Regulatory Science Approach aligned with FDA’s Project Optimus to select optimal dosing regimens and improve approval odds. As of March 13, 2026, it reported 2,660,039 common shares outstanding and held $1.4 million in Chiliz (CHZ) tokens with an unrealized gain of about $77,000 as part of an emerging digital asset treasury strategy.
The Chiliz Group Ltd, formerly HX Entertainment, reports a 13.0% beneficial ownership stake in Processa Pharmaceuticals’ common stock. It holds 305,644 shares with sole voting and dispositive power. This reflects its role as a significant strategic investor in the company.
The Chiliz Group’s total investment of approximately $1,443,784 includes an August 2025 purchase (later adjusted by a 1-for-25 reverse split) and a new February 13, 2026 purchase of 86,956 shares at $2.30 per share for $200,000, funded from internal working capital.
Processa Pharmaceuticals, Inc. reported that its Binding Term Sheet with Intact Therapeutics, signed on June 17, 2025, relating to PCS12852, expired on February 12, 2026. Because a definitive license agreement was never executed, the related proposed amendment to the existing License Agreement with Yuhan Corporation was also not entered into.
With the expiration of the Term Sheet, neither Processa nor Intact Therapeutics has any further obligations under that agreement, effectively ending the previously contemplated PCS12852 licensing arrangement under these terms.
Processa Pharmaceuticals received an amended Schedule 13G showing that investors Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively reported beneficial ownership of 200,000 shares of common stock issuable upon exercise of a warrant held by Intracoastal.
As of December 31, 2025, these warrant shares represented approximately 8.1% of Processa’s common stock, based on 2,265,768 shares outstanding as of December 12, 2025 plus the 200,000 warrant shares. The filers report shared voting and dispositive power over all 200,000 shares and certify the holding is not for the purpose of changing or influencing control.